GEN3d
JPM: Roche Licenses Dyno Therapeutics’ AAV Vector for Neurological Gene Therapy
Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...
First of its kind gene therapy model offers hope for X-linked sideroblastic anemia treatment
Castruccio Castracani and his team developed a lentiviral vector that activated the human ALAS2 gene in erythroid cells, or ...
MedPage Today1mon
Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A
Opens in a new tab or window SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous ...
FierceBiotech5d
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
Business Wire1mon
Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials
development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers ...
The American Journal of Managed Care7d
Standardized Measurements Needed for AAVs in Gene Therapy, Study Finds
Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...
Gene Therapy Market To Hit Valuation Of US$ 42.26 Billion By 2033 | Astute Analytica
New Delhi, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.26 billion by 2033 at a CAGR ...
The American Journal of Managed Care15d
Gene Therapy Demonstrates High Efficacy in Severe β-Thalassemia
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...